Online citations, reference lists, and bibliographies.
← Back to Search

Vaccination Of Horses With A Recombinant Modified Vaccinia Ankara Virus (MVA) Expressing African Horse Sickness (AHS) Virus Major Capsid Protein VP2 Provides Complete Clinical Protection Against Challenge

Berta Alberca, K. Bachanek-Bankowska, M. Cabana, Eva Calvo-Pinilla, Elisenda Viaplana, L. Frost, S. Gubbins, A. Urniza, P. Mertens, J. Castillo-Olivares
Published 2014 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Highlights • A recombinant modified Vaccinia Ankara virus expressing VP2 of African horse sickness virus serotype 9 was generated.• Four horses were vaccinated on days 0 and 20. Three unvaccinated controls were used.• Vaccinated and control horses were challenged intravenously with 107.4TCID50 of AHSV-9 on day 34 of the study.• At challenge, vaccinates had virus neutralising antibodies but were negative for antibodies to AHSV-VP7.• All vaccinates were completely protected against clinical signs of African horse sickness.
This paper references
10.1128/MCB.5.12.3403
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.
S. Chakrabarti (1985)
10.1007/978-3-7091-6823-3_17
New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles.
P. Roy (1998)
10.1006/VIRO.1998.9291
The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors.
J. Schaefer-Klein (1998)
10.1016/j.virusres.2013.12.002
Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
Eva Calvo-Pinilla (2014)
10.1371/journal.pone.0016503
A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model
J. Castillo-Olivares (2011)
10.1006/VIRO.1996.0304
Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.
M. Stone-Marschat (1996)
African horse sickness
R. DiazMontilla (1968)
10.1016/j.vetimm.2012.06.009
An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.
H. El Garch (2012)
10.1371/journal.pone.0005997
Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)
R. Chiam (2009)
10.1016/S0264-410X(01)00445-5
The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant.
M. Scanlen (2002)
African horse-sickness killed-virus tissue culture vaccine.
Y. Ozawa (1966)
10.1016/j.jviromet.2010.03.009
Development and optimisation of a duplex real-time reverse transcription quantitative PCR assay targeting the VP7 and NS2 genes of African horse sickness virus.
M. Quan (2010)
A new apporach to polyvalent immunization against African horse sickness
BJ Erasmus (1976)
10.1051/VETRES:2004021
African horse sickness.
P. Mellor (1998)
10.1016/0378-1135(92)90041-Q
African horse sickness in Spain.
M. Rodríguez (1992)
10.1016/0147-9571(94)90047-7
African horsesickness: pathogenesis and immunity.
T. G. Burrage (1994)
10.1016/j.vaccine.2009.05.044
Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
A. Guthrie (2009)
Inactivated African horse sickness virus cell culture vaccine.
H. Mirchamsy (1968)
10.1016/j.vaccine.2010.06.105
In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6.
B. V. von Teichman (2010)
Control and eradication of African horse sickness with vaccine.
J. M. Sánchez‐Vizcaíno (2004)
10.1016/0264-410X(94)90052-3
Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine.
J. A. House (1994)
Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus.
M. Romito (1999)
10.1177/104063870802000310
Real-Time Fluorogenic Reverse Transcription Polymerase Chain Reaction Assay for Detection of African Horse Sickness Virus
M. Agüero (2008)
10.1099/0022-1317-77-6-1211
Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.
J. Martínez-Torrecuadrada (1996)
10.1007/BF01863914
Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche
G. Kärber (2005)



This paper is referenced by
10.1016/j.jviromet.2016.09.009
Development and evaluation of a new lateral flow assay for simultaneous detection of antibodies against African Horse Sickness and Equine Infectious Anemia viruses.
Sofia Costa (2016)
10.1016/j.antiviral.2015.01.009
Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
Eva Calvo-Pinilla (2015)
10.1016/j.imbio.2015.09.002
Immune gene expression profiling of PBMC isolated from horses vaccinated with attenuated African horsesickness virus serotype 4.
Alri Pretorius (2016)
10.1016/j.virusres.2016.04.007
African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro.
F E Faber (2016)
10.1016/j.vaccine.2014.07.031
Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus
Y. Kanai (2014)
African horse sickness outbreak investigation and disease surveillance using molecular techniques
C. Weyer (2017)
10.1016/j.antiviral.2018.04.015
The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host
Eva Calvo-Pinilla (2018)
10.1016/j.vaccine.2017.04.005
Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
N. M. Manning (2017)
10.1111/evj.13353
African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination.
Javier Castillo-Olivares (2020)
10.1016/j.vaccine.2017.06.023
Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge
Valeria Lulla (2017)
10.1128/JVI.01052-15
VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV
S. V. D. van de Water (2015)
10.1016/j.vaccine.2019.10.087
Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
A. Marín-López (2019)
Seroprevalence of African horse sickness in Khartoum state , Sudan
H. M. H. Ibrahim (2018)
10.3390/v11090844
African Horse Sickness: A Review of Current Understanding and Vaccine Development
S. J. Dennis (2019)
10.20506/RST.34.2.2359
African horse sickness.
S. Zientara (2015)
10.1186/s12917-020-02540-y
Immune response of horses to inactivated African horse sickness vaccines
M. Rodríguez (2020)
10.1016/J.TRIVAC.2015.03.001
Immunization of horses with a polyvalent live-attenuated African horse sickness vaccine: Serological response and disease occurrence under field conditions
U. Molini (2015)
Identifying B-cell epitopes of African horse sickness virus serotype 4 recognised by antisera of immunised horses
E. M. Mathebula (2016)
10.4172/1745-7580.1000135
Immunoinformatics Prediction of Peptide-Based Vaccine Against AfricanHorse Sickness Virus
M. Abdelbagi (2017)
10.1186/s12917-019-2184-2
Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness
Daria A. Rutkowska (2019)
10.17159/SAJS.2015/20140331
Directed genetic modification of African horse sickness virus by reverse genetics
E. Vermaak (2015)
10.1111/tbed.12503
Development of a Luminex-Based DIVA Assay for Serological Detection of African Horse Sickness Virus in Horses.
A. Sánchez-Matamoros (2016)
10.1016/j.vaccine.2018.03.003
African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
P. V. van Rijn (2018)
10.3390/v11010035
Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor
A. Marín-López (2019)
10.1111/tbed.12968
Assessment of reproducibility of a VP7 Blocking ELISA diagnostic test for African horse sickness
M. Durán-Ferrer (2019)
10.1111/pbi.12783
Immunogenicity of plant‐produced African horse sickness virus‐like particles: implications for a novel vaccine
S. Dennis (2018)
10.14334/wartazoa.v28i4.1897
Awareness of African Horse Sickness as an Emerging Arbovirus Disease
A. Ratnawati (2019)
10.4102/ojvr.v84i1.1313
B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera
E. M. Mathebula (2017)
10.3201/eid2212.160718
African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004–2014
C. Weyer (2016)
10.1016/j.jevs.2020.102967
African Horse Sickness Fever in Vaccinated Horses: Short Communication.
U. Wernery (2020)
10.1016/j.virol.2016.07.010
Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus
Andelé M Conradie (2016)
Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus ( AHSV ) VP 2
Eva Calvo-Pinilla (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar